Based on ratings from 0 stock analysts, the Hepion Pharmaceuticals Inc stock price is expected to increase by 4009.59% in 12 months. This is calculated by using the average 12-month stock price forecast for Hepion Pharmaceuticals Inc. The lowest target is $30 and the highest is $30. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedHEPA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Hepion Pharmaceuticals Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HEPA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of HEPA.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Kumaraguru Raja Brookline Capital | Hold | Downgrade | Dec 7, 2023 | |
Kristen Kluska Cantor Fitzgerald | Overweight | $3.5 | Initiates | Feb 28, 2022 |
Brookline Capital | Buy | Initiates | Nov 22, 2019 |
When did it IPO
N/A
Staff Count
22
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. John Patrick Brancaccio CPA
Market Cap
$4.7M
In 2023, HEPA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HEPA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.